Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's Disease

NCT05891496 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05891496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05891496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's Disease
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
June 20, 2023
Completion date
September 8, 2025
Enrollment
23 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease